1Bleeding And Thrombosis In Patients With Out Of Hospital VT/VF Arrest Treated With2Extracorporeal Cardiopulmonary Resuscitation

3

Alejandra Gutierrez MD^{1,2}, Rajat Kalra MBChB, MS^{1,2}, Kevin Y. Chang MD³, Marie E. Steiner

Alejandra Gutierrez MD^{1,2}, Rajat Kalra MBChB, MS^{1,2}, Kevin Y. Chang MD³, Marie E. Steiner
 MD, MS^{4,5}, Alexandra M. Marquez MD, MSTR^{2,5}, Tamas Alexy MD, PhD^{1,2}, Andrea M. Elliott

6 $MD^{1,2}$, Meagan Nowariak BA^{6} , Demetris Yannopoulos $MD^{1,2}$, Jason A Bartos MD, Ph $D^{1,2}$

7

8 Affiliations

- ¹ Cardiovascular Division, Department of Medicine, University of Minnesota School of
 Medicine, Minneapolis, Minnesota
- ²Center for Resuscitation Medicine, University of Minnesota School of Medicine, Minneapolis,
 Minnesota
- ¹³ ³Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota
- ⁴Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota
- 15 School of Medicine, Minneapolis, Minnesota

⁵Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Minnesota

- 17 School of Medicine, Minneapolis, Minnesota
- ⁶University of Minnesota School of Medicine, Minneapolis, Minnesota
- 19 Short title: Bleeding and Thrombosis in eCPR
- Keywords: eCPR, ECMO, resuscitation, cardiac arrest, bleeding, thrombosis, coagulopathy,
 survival.
- 22
- 23 Word count: 4598
- 24 Corresponding author
- 25 Alejandra Gutierrez MD
- 26 Cardiovascular Division
- 27 University of Minnesota
- 28 420 Delaware Street SE
- 29 MMC 508
- 30 Minneapolis, MN 55455
- 31 Email: agb@umn.edu

33 Abstract

34 Background: Extracorporeal cardiopulmonary resuscitation (eCPR) improves outcomes after

out of hospital cardiac arrest (OHCA). However, bleeding and thrombosis are common

36 complications. The post cardiac arrest syndrome including trauma and altered hemostasis creates

challenges when balancing the risk of bleeding versus thrombosis. We aimed to describe the

incidence and predictors of bleeding and thrombosis and their association with in-hospital

39 mortality.

40 **Methods:** Consecutive patients presenting with refractory VT/VF OHCA between December

41 2015 and March 2022 who met criteria for eCPR initiation at our center were included. Patients

42 were anticoagulated with unfractionated heparin while on ECMO. Major bleeding was defined

43 by the extracorporeal life support organization's (ELSO) criteria as clinically significant bleed

44 associated with transfusion of ≥ 2 units of red blood cells in 24h or bleeding in a critical area.

Thrombosis was defined by clinical signs and symptoms and or imaging evidence of thrombi.

46 Adjusted analyses were done to seek out risk factors for bleeding and thrombosis and evaluate

47 their association with mortality.

48

Results: Major bleeding occurred in 135/200 patients (67.5%) with traumatic bleeding from

50 CPR in 73/200 (36.5%). Baseline demographics and arrest characteristics were similar between

51 groups. In multivariable regression analysis only fibrinogen was independently associated with

52 bleeding (aHR 0.98 per every 10mg/dl rise, 95% CI: 0.96-0.99). Patients who died had a higher

rate of bleeds per day (0.21 vs 0.03, p < 0.001) though bleeding was not significantly associated with in-hospital death (aHR 0.81, 95% CI: 0.55-1.19). A thrombotic event occurred in 23.5%

with in-hospital death (aHR 0.81, 95% CI: 0.55-1.19). A thrombotic event occurred in 23.5%
(47/200). Venous thromboembolism (VTE) occurred in 11% (22/200) and arterial thrombi in

(47/200). Venous thromboembolism (VTE) occurred in 11% (22/200) and arterial thrombi in
 15.5% (31/200). Clinical characteristics were comparable between groups. In adjusted analyses.

antithrombin III level on admission (aHR 0.97, 95% CI: 0.94-0.99) and use of dual anti-platelet

therapy (DAPT) (aHR 0.31, 95% CI: 0.11-0.86) were associated with the incidence of

thrombosis. Thrombosis was not associated with in-hospital death (aHR 0.65, 95% CI: 0.42-

60 1.03).

61

62 Conclusion: Bleeding is a frequent complication of eCPR that is associated with decreased

63 fibrinogen levels on admission. Thrombosis is less common occurring in 24% of the cohort.

64 Neither bleeding nor thrombosis was significantly associated with in-hospital mortality.

65

66 **Word count** 339

- 68 Abbreviations
- 69
- 70 CPR- cardiopulmonary resuscitation
- 71 DAPT- Dual antiplatelet therapy
- 72 eCPR- Extracorporeal cardiopulmonary resuscitation
- 73 PCI- percutaneous coronary intervention
- 74 OHCA- Out-of-hospital cardiac arrest
- 75 VA-ECMO- Veno arterial extracorporeal membrane oxygenation
- 76 VT/VF-Ventricular tachycardia/Ventricular fibrillation
- 77

- 78 Clinical Perspective:
- 79 What is new?
- In this large single center study with a protocolized approach to anticoagulation for
 patients with VT/VF OHCA bleeding as defined by ELSO major bleeding was common
 occurring in 68% of the cohort while thrombosis was less frequent occurring in 24% with
 the more than half of the events being arterial thrombi.
- Bleeding events are multifactorial including trauma from prolonged CPR, access site
 bleeding, and mucosal bleeding.
- Neither bleeding nor thrombosis is associated with overall in-hospital mortality.
- 87

88 What are the Clinical implications?

- The high incidence of bleeding and low incidence of thrombosis with the current
 approach to anticoagulation which often involves antithrombotic therapy reinforces the
 need for a better method to risk stratify patients to better tailor anticoagulation strategies.
- 92 The lack of association of bleeding and thrombotic events with mortality support a less
 93 aggressive anticoagulation strategy to minimize bleeding.

Introduction 94

Extracorporeal cardiopulmonary resuscitation (eCPR) improves survival after out-of-hospital 95 96 cardiac arrest (OHCA)(1-5). Incidence of EMS-assessed OHCA is estimated to be 350,000 in 2015 per AHA with 7% surviving with a good neurologic outcome(6). Mortality after OHCA has 97 98 remained poor with further worsening during the COVID 19 pandemic(6). The ARREST trial demonstrated that eCPR, including emergent cannulation with extracorporeal membrane 99 100 oxygenation (ECMO), improved the absolute survival to hospital discharge by 36% for patients with OHCA due to ventricular tachycardia or ventricular fibrillation (VT/VF) as the presenting 101 rhythm(1). Anticoagulation management of patients presenting with VT/VF OHCA supported by 102 eCPR is challenging with competing thrombogenic insults and high bleeding risk due to trauma 103 104 from prolonged CPR and coagulopathy related to cardiac arrest and the ECMO circuit. Bleeding is the most common complication of eCPR occurring in 8 to 70% of cases depending on the case 105 106 series and definition of bleeding used(2, 7, 8) while thrombotic rates are not well documented in the literature. 107

The bleeding risk associated with eCPR is multifactorial and its quantification is difficult. 108 109 The contact of blood with artificial surfaces and the sheer stress of the mechanical circuit leads to an acquired coagulopathy by activating the coagulation cascade. Therefore, patients are 110 anticoagulated to prevent thromboembolic events and oxygenator thrombosis(9). eCPR in the 111 setting of severe coronary artery disease presents further challenges as patients often require dual 112 antiplatelet therapy (DAPT) to protect the newly placed coronary stents (8, 10). Moreover, the 113 trauma associated with prolonged CPR and the inflammation and coagulopathy associated with 114 ischemia and reperfusion injury which hallmarks the post cardiac arrest syndrome enhances the 115 already heightened risk of bleeding and thrombosis(11). Data regarding the incidence and 116 predictors of bleeding and thrombosis as well as their impact on outcomes in VT/VF patients 117

- treated with eCPR is lacking. 118
- We aimed to describe the incidence, severity, and predictors of bleeding and thrombosis and 119 120 their association with in-hospital mortality.
- 121

Materials and Methods 122

123 2.1 Study population

Consecutive patients enrolled in the University of Minnesota (UMN) out-of-hospital 124 refractory VT/VF arrest protocol between December 2015 and March 2022 were eligible for 125 inclusion. Procedures were followed in accordance with the ethical standards of the IRB and in 126 accordance with the Helsinki Declaration of 1975. The study was reviewed and approved by the 127 128 Institutional Review Board (IRB) at the UMN (IRB #1703M11301). A waiver of informed consent was granted given the research was retrospective involving no more than minimal risk. 129

The UMN protocol has been previously described (3, 8, 12-16). Briefly, patients were 130 131 screened by paramedics (EMS) to include adults 18-75 years of age, with a shockable presenting rhythm and no return of spontaneous circulation (ROSC) after 3 shocks or shock-triggered 132 conversion to pulseless electrical activity or asystole, ongoing CPR with a Lund University 133 Cardiac Arrest System (LUCASTM), and an estimated transfer time to the closest cannulation site 134 of less than 30 minutes. At the cannulation site patients were assessed for the presence of the 135

following physiologic criteria: 1) end-tidal CO₂ >10mmHg; 2) PaO₂>50mmHg; 3) lactic acid 136 ≤18mmol/L. Patients meeting the physiologic criteria with ongoing arrest and those who 137 obtained ROSC but were unstable with refractory cardiogenic shock and hypotension despite 138 other interventions such as intra-aortic balloon pump placement (IABP; Maguet Cardiovascular, 139 Wayne, NJ, U.S.A.), vasopressors or inotropes underwent ultrasound-guided and fluoroscopy 140 assisted percutaneous V-A ECMO cannulation. Arterial (15-17Fr) and venous (25Fr) cannulas 141 were typically inserted in the ipsilateral common femoral artery and femoral vein, though 142 contralateral cannulation was used as needed. An antegrade perfusion cannula was inserted into 143 the superficial femoral artery ipsilateral to the arterial ECMO cannula to perfuse the distal lower 144 extremity. Per protocol, a heparin bolus was administered at the time of cannulation(17). All 145 146 patients underwent coronary angiography with percutaneous coronary intervention (PCI) as indicated following cannulation. An intravascular cooling catheter was placed for targeted 147 temperature management with a goal temperature of 34 C for 24 hours unless uncontrolled 148 bleeding necessitated a higher temperature target. The addition of an IABP was left to the 149 discretion of the interventional cardiologist to maintain coronary perfusion in the setting of 150 severe coronary artery disease or lack of cardiac pulsatility defined as an arterial pulse pressure 151 of less than 10 mmHg after initiation of V-A ECMO and PCI. All patients had non-contrast 152 computerized tomography (CT) of their head, chest, abdomen and pelvis upon admission given 153

the high prevalence of trauma associated with CPR(2, 18).

Patients were admitted to a centralized cardiac intensive care unit (CICU). A continuous
unfractionated heparin infusion was administered targeting an ACT goal of 180-200sec.
Anticoagulation targets were adjusted by the treating physician in patients with uncontrolled
bleeding. A heparin infusion of 2 U/mL in normal saline was administered at 3mL/hr
continuously through the antegrade perfusion cannula to maintain its patency. This infusion
continued regardless of the presence of bleeding.

161 *2.2 Study definitions and outcome variables*

Data was collected by retrospective chart review of medical records. The primary 162 outcome was in-hospital mortality. Secondary outcomes were major bleeding and thrombosis. 163 Major bleeding was defined by the ELSO criteria including clinically overt bleeding associated 164 with a hemoglobin fall of $\geq 2g/dl$ or ≥ 2 units of red blood cells transfused during a 24 hour 165 period(17). This included bleeding in a critical area defined as bleeding occurring in the 166 retroperitoneum, pulmonary, central nervous system, or requiring surgical intervention regardless 167 of the decline of hemoglobin or units of blood transfused. Given initial volume expansion, 168 hemolysis, intra-procedural blood loss, and frequent lab draws, it is common for patients to drop 169 their hemoglobin values significantly with successful V-A ECMO resuscitation after cardiac 170 arrest. Therefore, we scrutinized the medical records to identify clinical signs of bleeding noted 171 172 by the treatment team or present on imaging associated with transfusions or hemoglobin drop to determine major bleeding events. A declining hemoglobin level without clinical bleeding was 173 not considered a bleeding event. 174

The presence of thrombosis was determined by imaging studies with corresponding clinical correlates of venous or arterial thrombi. This was further classified into: 1 arterial thrombi including stroke as evidenced by imaging, thrombi in the left atrium, left ventricle, aortic valve or other arterial bed such as the superior mesenteric artery and oxygenator

thrombosis requiring exchange of the oxygenator and 2. Venous thrombi including DVT andIVC thrombosis, right atrial thrombi or pulmonary embolism.

181 The first arterial blood gas collected just prior to ECMO cannulation was used to 182 establish initial hemoglobin level. Other laboratory parameters were obtained from the first 183 complete set of blood work performed on arrival to the CICU.

184 2.3 Statistical Analysis

185 Continuous variables were represented as means with standard deviations and compared 186 using the t-test or analysis of variance (ANOVA) tests. Non-normal continuous variables were 187 represented as medians with interquartile ranges and compared with the Wilcox Rank-Sum test. 188 Categorical variables were represented as counts with proportions and compared with the chi-189 squared test.

190

To identify predictors of major bleeding, the association of age, CPR time, baseline use of 191 anticoagulation, use of DAPT during the admission, INR, fibrinogen, antithrombin III and 192 193 platelet count were first evaluated in unadjusted analyses. These factors were selected due to the established data suggesting their association with bleeding and thrombosis. Predictors that were 194 significant at p < 0.20 in unadjusted analyses were included via stepwise selection in an adjusted 195 196 (multivariable) Cox proportional hazards model to determine which factors remained significant 197 predictors of major bleeding events. The same method was used to determine which clinical factors were significant predictors of thrombotic events. 198

198

Cox multivariable regression analyses were done to account for the effect of clinically 200 important covariates in the association between major bleeding and thrombosis with in-hospital 201 death. Age, sex, CPR time, use of DAPT were chosen *a priori* as covariates in Cox multivariable 202 regression analyses. These variables were chosen due to their acknowledged associations with 203 bleeding and thrombotic events. The proportional hazard assumption was checked using 204 Schoenfeld's residuals. To overcome immortal time bias for VTE, landmark analysis was 205 performed using 5 days as the landmark time for this survival analysis(19). For the survival 206 analyses that assessed the association of major bleeding events with in-hospital death, major 207 thrombosis was also included as a covariate in the multivariable analyses, due to the tendency of 208 thrombosis to affect clinical anticoagulation management. Similarly, major bleeding events were 209 included as a covariate in the survival analyses that assessed the association of thrombosis with 210 in-hospital death. 211

212

In-hospital death may be a competing event for the occurrence of major bleeding events 213 and/or thrombosis during treatment with VA-ECMO. Thus, competing risk analyses were 214 performed to evaluate factors that may be associated with major bleeding events and thrombosis, 215 respectively. The cumulative incidence of major bleeding events and thrombosis was estimated 216 using Gray's test. In-hospital death due to causes other than bleeding events or thrombosis were 217 the competing events. The results were represented as sub-hazard ratios (sHRs) with 95% 218 confidence intervals. The Fine-Gray model was used to perform multivariable regression. The 219 level of statistical significance was set at < 0.05 for all analyses. The analyses were done with 220 221 IBM SPSS v28 (Chicago, IL, U.S.A.) and StataMP 17.0 (College Station, TX, U.S.A.). 222

223 **Results**

224 *3.1 Study population*

A total of 260 patients presented within criteria with a VT/VF cardiac arrest and achieved an organized rhythm at the end of the cardiac catheterization case. 23% of patients achieved stable ROSC and did not require V-A ECMO to stabilize their cardiogenic shock and were therefore excluded from this analysis. The final study population consisted of 200 patients.

Baseline characteristics are shown in **Table 1**. The majority of the cohort was male 229 (81%) with a mean age of 57 (12.2) years. Comorbid conditions included coronary artery disease 230 in 26% (52/200), congestive heart failure (CHF) in 12.5% (25/200), diabetes in 24.5% (49/200) 231 and hypertension in 35.5% (71/200). Prior to admission medications included: a direct oral 232 233 anticoagulant in 6/200 (3%), a vitamin K antagonist in 4/200 (2%), aspirin in 29/200(14.5%) and a P2Y12 inhibitor in 3/200 (1.5%). The average CPR time from 911 call or identified arrest by 234 EMS to V-A ECMO initiation was 62± 19 minutes. An IABP was placed in 71% (142/200) of 235 the cohort. Revascularization was performed in 121/200 (60.5%) of patients and DAPT was 236 237 given to 62.0% (124/200) of the cohort.

The hemoglobin on initial presentation to the emergency department or catheterization lab was 12.6 \pm 2.6 g/dl. Other lab parameters were obtained at the time of arrival to the CICU. Most blood tests were above normal limits (**Figure 1**) including: ALT (187 \pm 199 U/L), AST (372 \pm 410 U/L), INR(2.0 \pm 0.9), ACT (224 \pm 63), PTT (195 \pm 72sec) and D-dimer(16 \pm 7Ug/mL). Antithrombin III levels were often below the normal range of our laboratory (>85%) with an average of 59.6% \pm 16.9 while the average fibrinogen of our cohort was within normal limits at 234 \pm 109 mg/dL.

245 3.2 Predictors of Bleeding

246 Major bleeding was common occurring in 135/200 patients (67.5%). There was more than one site of bleeding in 91/200 (45.5%) patients. Minor bleeding which did not meet criteria 247 for ELSO major bleeding occurred in 21/200(10.5%) of patients and there was no clinical 248 evidence of bleeding in 44/200 (22%) patients. Details regarding major bleeding site are shown 249 250 in Figure2A. The most common site of major bleeding was access site bleeding. This was present in 106/200 (53.0%) with 6 patients requiring a surgical intervention to repair this. 251 252 Intracranial bleeding (ICH) occurred in 10/200 (5.0%) including 3 cases of subarachnoid hemorrhage, 2 intraventricular hemorrhages, and 5 intraparenchymal hemorrhages. The median 253 254 day of diagnosis of ICH was 3 (1,7) days. CPR-related trauma was frequent, occurring in 73/200 (36.5%) of the cohort including mediastinal hematoma in 51/200(26%), 14/200(7%) with 255 256 pericardial bleeding, 11% (22/200) with a hemothorax and 7% (14/200) intraperitoneal bleeding. Gastrointestinal bleeding was clinically diagnosed in 33/200 (16.5%) patients. Most cases were 257 managed medically with only 6/200 cases (4.7%) undergoing upper endoscopy. The majority of 258 259 bleeding events (92%) happened while the patients were on V-A ECMO. The first major 260 bleeding event was frequently within the first days of hospitalization, with a median time from admission to bleeding of 1 (0,2) day with 50% of patients bleeding on day 0-1 of admission and 261 74% of all bleeding events occurring before the third day of the hospitalization (Figure 2B). 262

Baseline comorbidities were comparable between those who had major bleeding and those without major bleeding (**Table 1**). In unadjusted analysis, those with a bleeding event had

a lower hemoglobin (12.3 vs 13.1g/dL; p=0.05), platelets (179 vs 200 x 10e3/uL, p=0.04), 265 266 fibrinogen (218 vs 266 mg/dL, p=0.004), and antithrombin III levels (57 vs 65%, p<0.001) on admission (Figure 1). Our patients had an average D-dimer of 15.9(7.2) vs 15.2(7.0) ug/mL for 267 268 bleeding and non-bleeding patients respectively with a normal for our laboratory being 0.0-0.5ug/mL and no significant difference among groups (p=0.52). 269 Use of procedural anticoagulation and antiplatelet medications were not associated with 270 bleeds. The use of iib/iiia inhibitors and cangrelor was uncommon (6/200(3.0%) and 271 16/200(8.0%), respectively). The average dose of heparin given for ECMO cannulation and rate 272 of PCI was not significantly different between groups. 273 In unadjusted analyses age, antithrombin III, and fibrinogen met the prespecified p <0.20 274 threshold for inclusion in the adjusted model. In adjusted analyses, only fibrinogen was 275 276 associated with incident major bleeding events with every 10 unit rise in fibrinogen associated with 0.98 times the hazard of major bleeding (HR 0.98, 95% CI: 0.95-0.99) (Central Figure). 277 278 The risk of bleeding seemed to heighten with fibrinogen levels below 300mg/dL (with 47.7% of patients having a major bleed in those with a fibrinogen > 300 mg/dL vs 72.8% in those with a 279 280 fibrinogen <300mg/dL, p=0.003) (Figure 2C). 281 3.3 Outcomes associated with bleeding 282

In unadjusted analyses, the occurrence of a major bleeding event was not significantly
associated with in-hospital death. Similarly, after adjustment for clinically relevant factors,
having an ELSO major bleeding event was not associated with in-hospital death (aHR 0.81, 95%
CI: 0.55-1.19).

Hospital course and outcomes are shown in **Table 2.** In unadjusted analysis, major 287 bleeding was associated with higher transfusion needs with patients who had a bleeding event 288 receiving a median of 7(4,12) units of red blood cells, 2(0,5) units of platelets and 1(0,3) unit 289 of fresh frozen plasma. Patients who had a bleeding event had similar rates of renal replacement 290 therapy(30.4 vs 21.5%; p=0.25), extubation (29.6 v 20.0%; p=0.20) and successful V-A ECMO 291 292 decannulation (48.1 vs 32.3%;p=0.19). For those patients who survived to extubation, the length of mechanical ventilation was longer in patients who had a major bleeding event (9 vs 6 days, 293 p=0.05). The median length of hospital stay was 8 (2,21) days. Having a bleeding event was 294 associated with a longer length of hospitalization with a median of 10(3,22) compared to 4(2,14)295 (p=0.01)days of admission. 296

In the adjusted competing risks analyses, age (sHR 1.01, 95% CI: 0.99-1.03), sex (sHR 0.75, 95% CI:0.44-1.27), CPR time (sHR 1.00, 95% CI: 0.99-1.01), use of DAPT during the hospitalization (sHR: 0.96, 95% CI: 0.62-1.49), were not associated with major bleeding or all-cause in-hospital mortality.

- 301
- 302 *3.5 Thrombotic events*

Arterial or venous thrombotic events were identified in 23.5% (47/200) patients. The sites of thrombi are shown in **Figure 3A**. Venous thromboembolism including deep vein thrombosis (DVT), right atrial thrombi and pulmonary embolism (PE) occurred in 22/200 (11.0%). Arterial thromboembolism was seen in 31/200 (15.5%) with 6 patients experiencing both arterial and

307 venous thrombi during their hospitalization. Oxygenator thrombosis requiring exchange of the 308 membrane was uncommon, occurring in 1.5% of the cohort(3/200). Two of these occurred the

- day of admission soon after cannulation and the other one occurred 12 days after cannulation.
- 310 Despite continuous anticoagulation infusion through the reperfusion cannula, problems with
- thrombus formation in the tubing or catheter occurred in 5 patients (2.5%). Two other patients
- (1%) had lower limb ischemia requiring thrombectomy to salvage the limb. Thrombosis occurred
- at a median of 5(1,12) days from the day of admission. Arterial thrombi presented earlier (2 [1,6]
- days) compared to VTE events (12 days [9,16]) Figure 3B.

There were no differences in baseline characteristics, comorbidities or arrest 315 characteristics in the groups with and without thrombosis (Table 1). Those who had a thrombotic 316 317 event had a higher fibrinogen level (264 vs 225, p=0.03) and a lower ALT (141 vs 202, p=U/L) compared to those who did not have a thrombotic event (Figure 1). Treatment characteristics of 318 319 patients with and without thrombosis are shown in Table 3. The use of an IABP was not associated with increased thrombotic events. A thrombus in the inferior vena cava was detected 320 in 6/300 (3.0%) accounting for 6/22 (27%) of all the deep venous thromboembolisms. Length of 321 V-A ECMO cannulation was associated with a longer time on V-A ECMO predominantly due to 322 323 longer runs in patients with arterial thrombi but was not associated with the rate of VTE (Table 3). In the univariate analyses, age, CPR time, baseline use of anticoagulation, DAPT 324 administration, antithrombin III, and platelet count met the pre specified p <0.20 threshold for 325 inclusion in the adjusted model. In the adjusted analyses, a higher level of antithrombin III (aHR 326 0.97, 95% CI: 0.94-0.99) and use of DAPT (aHR 0.31, 95% CI: 0.11-0.86) were associated with 327 a reduced incidence of thrombosis (Central Figure). 328

329

330 *3.6 Outcomes associated with thrombosis*

Patients who had a thrombotic event had a higher number of transfusions of red blood
cells and platelets (7 versus 4 units; p=0.01 and 2 versus 1 units; p=0.005 respectively) (Table
3). There was no significant difference in terms of renal replacement therapy or rates of
extubation. However, the length of stay was significantly longer for those who had a thrombotic
event.

In the unadjusted analyses, the occurrence of a thrombotic event was not associated with 336 in hospital death (Table 3). After adjustment for age, sex, CPR time, use of DAPT and the 337 occurrence of major bleeding, the occurrence of thrombosis was not associated with in-hospital 338 death (aHR 0.65, 95% CI: 0.42-1.03). Adjustment for competing risk of death also negated the 339 340 difference observed in the unadjusted analysis. When stratified by type of thrombosis, VTE was associated with in hospital mortality in unadjusted (Table 3) and adjusted analysis (aHR 0.22, 341 95% CI 0.09-0.60). The rate of VTE was associated with the length of stay with a rate of 0.01+/-342 0.023 per day for those who survived compared to 0.003 ± 0.015 for those who died (p=0.008). 343 Each additional day of hospitalization was associated with an OR of 1.05 of VTE (95% CI: 1.0-344 1.1, p<0.001) making it very sensitive to survival bias. In a landmark analysis, excluding patients 345 who died before the first 5 days of admission (none of whom had a VTE), VTE was no longer 346 associated with in hospital mortality (HR 0.44, 95% CI: 0.17-1.12). 347 348

Arterial site thrombosis was not associated with in hospital death in unadjusted (**Table 3**) or adjusted analysis (aHR1.2, 95% CI 0.73-1.94). In the adjusted competing risks analyses, only age was associated with increased arterial site thrombosis (sHR 1.04, 95% CI 1.00-1.09).

353 Discussion

352

In this large observational single center study, we report the incidence and risk factors 354 associated with bleeding and thrombosis and their association with in-hospital mortality. Major 355 bleeding as defined by ELSO is a common complication of eCPR, affecting 67.5% of our cohort. 356 In multivariable analysis, the only risk factor associated with bleeding was decreasing levels of 357 fibringen. Thrombosis was less common than bleeding, occurring in 23.5% of patients with 358 359 11.0% of patients having a VTE and 15.5% an arterial thrombi. A higher level of antithrombin III on admission and the administration of DAPT was associated with decreased thrombotic risk. 360 Neither bleeding nor thrombosis was associated with in-hospital mortality when results were 361 adjusted for clinically significant factors. 362

Reported rates of bleeding in the eCPR population vary widely(5, 20-25), but are higher 363 than those of other types of ECMO including V-A ECMO for other cardiac indications (21, 25) 364 or V-V ECMO (21). The heightened risk of bleeding is thought to be related to trauma from 365 prolonged CPR, hypothermia, and coagulopathy associated with the post cardiac arrest 366 syndrome(5, 11, 22). In our cohort, we found an incidence of intracranial hemorrhage of 5% 367 which is similar to that reported in other eCPR cohorts (4.3-5.6%)(21, 23), while 67.5% of 368 patients had major bleeding events. Although elevated, this is concordant with other eCPR 369 370 cohorts, including the study by Otani et al published in 2018 which reported a 70% (71/233) bleeding rate(22). In their study, major bleeding was assessed by BARC (Bleeding Academic 371 Research Consortium) criteria defined as Type 3 or higher correlating to overt bleeding plus a 372 hemoglobin drop of $\geq 3g/dL$ within 24 h of hospital admission(22). Similarly, the CHEER study 373 had a bleeding rate of 70% (18/26) though they do not specify how they defined this outcome(5). 374 375 However other studies of eCPR patients quote lower bleeding rates including: 38% as defined by the BARC type 3 or higher (20), 39% assessed by BARC type 3b or higher(24), 26% per ELSO 376 criteria in the ELSO registry(25), and 20-22% without a clear definition of major bleeding(23, 377 26). The discrepancy is likely due to the various definitions of bleeding, with ELSO-defined 378 major bleeding being a more sensitive criteria including a drop of $\geq 2g/dl/24h(26)$. 379

In unadjusted analysis, decreased levels of fibrinogen, antithrombin III and platelet count 380 were associated with increased risk of major bleeding. Prior studies on eCPR patients suggest 381 that hyperfibrinolysis may increase bleeding risk. In a study including 133 patients, higher D-382 dimer level on admission (18.8ug/mL vs 6.7,ug/mL) was associated with major bleeding(22)... 383 We did not find significant associations between initial D-dimer and bleeding, but the D-dimer 384 levels of our cohort were very elevated (15.7 ± 0.5 ug/mL (normal for our laboratory: 0.0-385 0.5 ug/mL) and frequently reported as >20 ug/mL. This may have led to an underestimation of 386 the actual D-dimer levels in bleeding patients and may explain the disparate findings. However, 387 388 markers of coagulation factor consumption including low fibrinogen and low antithrombin III were associated with bleeding. In adjusted analysis, decreased level of fibrinogen was the only 389 variable associated with increased bleeding risk. Another study including all V-A ECMO 390 391 patients identified fibringen among other factors to be predictive of bleeding (25). Low platelet count, elevated D-dimer, and low fibrinogen has been observed in other eCPR populations with 392 an elevated disseminated coagulation score (DIC) score being associated with mortality(24, 27). 393

These studies excluded patients on DAPT whereas we had a significant proportion of patients on
 DAPT and found a persistent association with markers of consumption and increased bleeding
 risk.

Major bleeding increased in-hospital morbidity but was not associated with increased 397 mortality. The lack of association with in-hospital mortality diverges from some published 398 ECMO studies where bleeding has been associated with increased mortality (9, 21, 28). In 399 400 contrast to our data these studies included veno-venous and veno-arterial ECMO support(9, 21, 28) and pediatric and adult patients(9, 21). Further, it is possible that bleeding as defined by the 401 criteria for ELSO major bleeding is an insensitive marker of major events. However, other 402 studies have reported a lack of association between bleeding and in hospital death. In an 403 404 unadjusted analysis utilizing BARC type 3 or higher by Otani et al, the rates of bleeding were similar in survivors and non-survivors treated with eCPR (46v33%, p=0.44). Similarly in a study 405 406 by Sahli et al including all-comers requiring ECMO support, development of bleeding 407 complications during ECMO was not an independent predictor of mortality though they did not provide their definition of bleeding(23). Major bleeding was associated with increased 408 transfusion needs in this study in agreement with prior reports in the literature (9, 21, 23, 25) and 409 410 with longer time on mechanical ventilation.

Thrombotic complications are sparsely reported in the eCPR literature. We found a rate 411 of 22.5% which is similar to that published in another study including eCPR patients with a rate 412 of thrombosis of 21%(20), but higher than the 7% reported in a recent meta-analysis(26). The 413 risk of limb ischemia in the literature is around 16-24%(20, 26) whereas we had a much lower 414 rate of 1%. We routinely place antegrade perfusion catheters at the time of cannulation and 415 infuse heparin through that catheter. Further, our patients were uniformly eCPR patients with an 416 anticoagulation strategy that utilized an unfractionated heparin infusion targeting an ACT of 180-417 200 sec. This is not a universal practice and may account for these differences(26). In our study, 418 predictors of thrombosis included lower levels of antithrombin III and patients without DAPT 419 420 administration. Data regarding risk factors for thrombosis is lacking. In a meta-analysis including all types of ECMO, the anticoagulation strategy was not significantly associated with thrombotic 421 risk though the use of antiplatelet therapy was not reported(26). 422

423 In this cohort, thrombosis was not associated with increased mortality. Consistent with other eCPR(20) and general ECMO (26) literature, we did not find any association between 424 survival and thrombosis(20). Thrombotic complications of eCPR include arterial and venous 425 thrombi and their pathophysiology differs significantly. Arterial thrombi typically present in the 426 first few days of admission while patients are highly reliant on the ECMO circuit and the ejection 427 fraction is frequently limited (16). The association of VTE with in-hospital mortality is likely 428 due to immortal time bias, with a rate of thrombosis per day of 0.01 ± 0.02 for those who 429 survived vs 0.003+/- 0.02 for those who died. VTE is highly dependent on length of hospital stay 430 as has been shown in numerous cohorts including our data where the risk of VTE increased by 431 5% per each additional day of hospitalization(29, 30). A landmark analysis was performed to 432 433 overcome this important survival bias. In a study including routine ultrasound evaluation for VTE post decannulation, DVT was found in 15/30 (50%) of those who survived to decannulation 434 where V-V ECLS and length of cannulation were the only predictors of VTE(31). In our cohort 435 436 the length of VA ECMO cannulation was not associated with the rate of VTE. Our rate of DVT was significantly lower however, our cohort did not include V-V ECMO, and we only performed 437 ultrasounds when clinically indicated. Despite the underreported rate of thrombosis eCPR 438

patients are anticoagulated aggressively with more than half of them receiving antiplatelet
therapy in addition to heparin given the burden of acute coronary syndrome as the cause of

441 VT/VF arrest. Given the high rate of bleeding and low thrombotic risk in our eCPR population,

442 further research should evaluate anticoagulation strategies to find the optimal approach that

443 minimizes risk of bleeding without increasing thrombotic sequelae (26).

Given the retrospective nature of the study, some limitations are inevitable. While this 444 445 represents one of the largest single center cohorts published, its small size may limit discrimination of small differences between groups. Despite performing adjusted analyses, we 446 cannot account for potential confounding from variables that were not included in the model. 447 The study was observational and change in anticoagulation management in response to bleeding, 448 449 thrombotic events, or lab values was not protocolized or mandated and was not included in the analysis. Finally, despite using survival analysis and competing risk analysis, survival bias is 450 451 unavoidable. Patients who die are no longer able to experience a bleeding or thrombotic event therefore our results should be interpreted with caution. 452

453

454 Conclusions

In this large study of eCPR patients, 67.5 % of patients experienced major bleeding as defined by

ELSO, while 23% of our cohort experienced thrombosis. Lower fibrinogen was associated with

increased bleeding risk while the use of DAPT and lower antithrombin III levels on admission

458 was associated with decreased thrombotic risk. Major bleeding was not associated with in-

hospital mortality, but both thrombosis and major bleeding were associated with in-hospital
 morbidity with higher transfusion needs and longer mechanical ventilation days for those who

460 bled. There is a need to assess optimal anticoagulation and antiplatelet regimens that minimize

462 bleeding risk without increasing thrombotic consequences.

463 **Disclosure statement:** The authors report no financial relationships or conflicts of interest 464 regarding the content herein as well as no other relevant relationships to industry.

465

466

468 References

Yannopoulos D, Bartos J, Raveendran G, Walser E, Connett J, Murray TA, et al. Advanced
 reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular
 fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet.
 2020;396(10265):1807-16.

Bartos JA, Carlson K, Carlson C, Raveendran G, John R, Aufderheide TP, et al. Surviving refractory
 out-of-hospital ventricular fibrillation cardiac arrest: Critical care and extracorporeal membrane
 oxygenation management. Resuscitation. 2018;132:47-55.

Bartos JA, Frascone RJ, Conterato M, Wesley K, Lick C, Sipprell K, et al. The Minnesota mobile
extracorporeal cardiopulmonary resuscitation consortium for treatment of out-of-hospital refractory
ventricular fibrillation: Program description, performance, and outcomes. EClinicalMedicine. 2020;2930:100632.

Bartos JA, Grunau B, Carlson C, Duval S, Ripeckyj A, Kalra R, et al. Improved Survival With
 Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated
 With Prolonged Resuscitation. Circulation. 2020;141(11):877-86.

5. Stub D, Bernard S, Pellegrino V, Smith K, Walker T, Sheldrake J, et al. Refractory cardiac arrest
treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). Resuscitation.
2015;86:88-94.

486 6. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and
487 Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation.

488 2022;145(8):e153-e639.

4897.Inoue A, Hifumi T, Sakamoto T, Kuroda Y. Extracorporeal Cardiopulmonary Resuscitation for Out-490of-Hospital Cardiac Arrest in Adult Patients. J Am Heart Assoc. 2020;9(7):e015291.

491 8. Yannopoulos D, Bartos JA, Martin C, Raveendran G, Missov E, Conterato M, et al. Minnesota
492 Resuscitation Consortium's Advanced Perfusion and Reperfusion Cardiac Life Support Strategy for Out493 of-Hospital Refractory Ventricular Fibrillation. J Am Heart Assoc. 2016;5(6).

494 9. Mazzeffi M, Greenwood J, Tanaka K, Menaker J, Rector R, Herr D, et al. Bleeding, Transfusion,
495 and Mortality on Extracorporeal Life Support: ECLS Working Group on Thrombosis and Hemostasis. Ann
496 Thorac Surg. 2016;101(2):682-9.

497 10. Yannopoulos D, Bartos JA, Raveendran G, Conterato M, Frascone RJ, Trembley A, et al. Coronary
498 Artery Disease in Patients With Out-of-Hospital Refractory Ventricular Fibrillation Cardiac Arrest. Journal
499 of the American College of Cardiology. 2017;70(9):1109-17.

500 11. Wada T. Coagulofibrinolytic Changes in Patients with Post-cardiac Arrest Syndrome. Front Med501 (Lausanne). 2017;4:156.

Yannopoulos D, Bartos JA, Aufderheide TP, Callaway CW, Deo R, Garcia S, et al. The Evolving
 Role of the Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital

504 Cardiac Arrest: A Scientific Statement From the American Heart Association. Circulation.

505 2019;139(12):e530-e52.

506 13. Gutierrez A CC, Kalra R, Elliott AM, Yannopoulos D, Bartos JA. Outcomes associated with delayed
 507 enteral feeding after cardiac arrest treated with veno-arterial extracorporeal membrane oxygenation
 508 and targeted temperature management. Resuscitation. 2021;164:20-6.

509 14. Bartos JA, Clare Agdamag A, Kalra R, Nutting L, Frascone RJ, Burnett A, et al. Supraglottic airway

510 devices are associated with asphyxial physiology after prolonged CPR in patients with refractory Out-of-

511 Hospital cardiac arrest presenting for extracorporeal cardiopulmonary resuscitation. Resuscitation.

512 2023;186:109769.

15. 513 Gutierrez A, Kalra R, Elliott AM, Marquez A, Yannopoulos D, Bartos JA. Acute lung injury and 514 recovery in patients with refractory VT/VF cardiac arrest treated with prolonged CPR and veno-arterial 515 extracorporeal membrane oxygenation. Resuscitation. 2023;182:109651. 516 16. Kalra R, Bartos JA, Kosmopoulos M, Carlson C, John R, Shaffer A, et al. Echocardiographic 517 evaluation of cardiac recovery after refractory out-of-hospital cardiac arrest. Resuscitation. 518 2020;154:38-46. 519 ELSO anticoagulation guideline: 2014 The Extracorporeal Life Support Organization (ELSO) Ann 17. 520 Arbor, MI, USA [Available from: https://www.elso.org/Portals/0/Files/elsoanticoagulationguideline8-521 2014-table-contents.pdf. 522 Richardson ASC, Tonna JE, Nanjayya V, Nixon P, Abrams DC, Raman L, et al. Extracorporeal 18. 523 Cardiopulmonary Resuscitation in Adults. Interim Guideline Consensus Statement From the 524 Extracorporeal Life Support Organization. ASAIO J. 2021;67(3):221-8. 525 19. Morgan CJ. Landmark analysis: A primer. J Nucl Cardiol. 2019;26(2):391-3. 526 20. Dennis M, McCanny P, D'Souza M, Forrest P, Burns B, Lowe DA, et al. Extracorporeal 527 cardiopulmonary resuscitation for refractory cardiac arrest: A multicentre experience. Int J Cardiol. 528 2017;231:131-6. 529 21. Li C, Cai T, Xie H, Wang L, Yang F, Du Z, et al. Risk factors and outcomes for patients with 530 bleeding complications receiving extracorporeal membrane oxygenation: An analysis of the Chinese 531 Extracorporeal Life Support Registry. Artif Organs. 2022. 532 22. Otani T, Sawano H, Natsukawa T, Matsuoka R, Nakashima T, Takahagi M, et al. D-dimer predicts 533 bleeding complication in out-of-hospital cardiac arrest resuscitated with ECMO. Am J Emerg Med. 534 2018;36(6):1003-8. 535 23. Sahli SD, Kaserer A, Braun J, Halbe M, Dahlem Y, Spahn MA, et al. Predictors associated with 536 mortality of extracorporeal life support therapy for acute heart failure: single-center experience with 537 679 patients. J Thorac Dis. 2022;14(6):1960-71. 538 Mecklenburg A, Stamm J, Angriman F, Del Sorbo L, Fan E, Soeffker G, et al. Impact of therapeutic 24. 539 hypothermia on bleeding events in adult patients treated with extracorporeal life support peri-cardiac 540 arrest. J Crit Care. 2021;62:12-8. 541 Willers A, Swol J, van Kuijk SMJ, Buscher H, McQuilten Z, Ten Cate H, et al. HEROES V-A-25. 542 HEmoRrhagic cOmplications in veno-arterial Extracorporeal life Support-Development and internal 543 validation of a multivariable prediction model in adult patients. Artif Organs. 2022. 544 Sy E, Sklar MC, Lequier L, Fan E, Kanji HD. Anticoagulation practices and the prevalence of major 26. 545 bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation: 546 A systematic review and meta-analysis. J Crit Care. 2017;39:87-96. 547 27. Ruggeri L, Franco A, Alba AC, Lembo R, Frassoni S, Scandroglio AM, et al. Coagulation 548 Derangements in Patients With Refractory Cardiac Arrest Treated With Extracorporeal Cardiopulmonary 549 Resuscitation. J Cardiothorac Vasc Anesth. 2019;33(7):1877-82. 550 28. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, et al. Factors associated with 551 outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Crit 552 Care. 2013;17(2):R73. 553 29. Salomon B, Dasa V, Krause PC, Hall L, Chapple AG. Hospital Length of Stay Is Associated With 554 Increased Likelihood for Venous Thromboembolism After Total Joint Arthroplasty. Arthroplast Today. 555 2021;8:254-7 e1. 556 Agarwal G, Hajra A, Chakraborty S, Patel N, Biswas S, Adler MK, et al. Predictors and mortality 30. 557 risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of 558 observational studies. Ther Adv Cardiovasc Dis. 2022;16:17539447221105013.

- 559 31. van Minnen O, van den Bergh WM, Droogh JM, Koehorst L, Lagrand WK, Raasveld SJ, et al.
- 560 Incidence and risk factors of deep vein thrombosis after extracorporeal life support. Artif Organs.
- 561 2022;46(9):1893-900.

562

564 1. **Figures**

Figure 1. Hematologic markers on arrival to the intensive care unit stratified by patients with and without thrombosis and those with and without major bleeding.

567 Figure 2. Characteristics of major bleeding events. A. Sites of major bleeding. B. Percentage of

admitted patients who had a major bleeding event. C. Percentage of patients who had a majorbleeding event depending on admission fibrinogen level.

570 Figure 3. Characteristics of thrombotic events. A. Percentage of patients with different sites of

571 thrombosis with VTE(green) and arterial thrombosis (pink). B. Percentage of admitted patients

572 who present thrombosis per day of admission. * arterial thrombosis refers to aorta and/or SMA

- 573 thrombosis.
- 574 Figure 4. Central figure. Rates of bleeding and thrombosis. Multivariable model of risks of
- 575 bleeding and thrombosis. * denotes statistical significance.
- 576

578 579 2. **Tables**

580 581 582

Table 1. Demographics, baseline and arrest characteristics of patients with and without major bleeding and with and without a thrombotic event.

	Overall	No major	Major	Р	No	Thrombos	Р
	Cohort (N=200)	bleeding (N=65)	bleeding (N=135)	value	thrombotic events (N=153)	is (N=47)	value
Baseline Characte		•					
Gender, Male	162(81.0)	54(83.1)	108(80.0)	0.74	122(79.7)	40(85.1)	0.54
Age, years	57.0(12.2)	55.5(12.6)	57.7(11.9)	0.24	56.8(12.1)	57.8(12.5)	0.61
BMI, Kg/m ²	30.7(6.2)	30.2(25.9,35 .4)	29.7(26.8,33. 8)	0.73	29.7(26.8,33 .7)	30.6(25.9, 33.9)	0.99
Comorbidities		· · ·	•	-			
Coronary artery disease	52(26.0)	14(21.5)	38(28.1)	0.41	38(24.8)	14(29.8)	0.62
Congestive Heart Failure	25(12.5)	6(9.2)	19(14.1)	0.48	18(11.8)	7(14.9)	0.77
Diabetes mellitus	49(24.5)	14(21.5)	35(25.9)	0.62	35(22.9)	14(29.8)	0.44
End stage renal	4(2.0)	1(1.5)	3(2.2)	1.00	3(2.0)	1(2.1)	1.00
disease							
Hyperlipidemia	49(24.5)	13(20.0)	36(26.7)	0.39	35(22.9)	14(29.8)	0.44
Hypertension	71(35.5)	17(26.2)	54(40.0)	0.08	49(32.0)	22(46.8)	0.09
Arrest characterist	tics and treatme	ents prior to IC	U admission				
CPR time, min	62(19)	61(19)	63(20)	0.84	62(20)	61(17)	0.69
IABP	142(71.0)	42(64.4)	100(74.1)	0.23	105(68.6)	37(78.7)	0.25
Heparin bolus	12578(4353	12585(5202	12575(3901)	0.99	12544(4588)	12682(358	0.85
during))				8)	
cannulation and							
PCI, Units							
Cangrelor	16(8.0)	3(4.6)	13(9.6)	0.34	11(7.2)	5(10.6)	0.65
GP iib/iiia	6(3.0)	2(3.1)	4(3.0)	1.000	3(2.0)	3(6.4)	0.29
inhibitor							
DAPT	124(62.0)	33(50.8)	91(67.4)	0.03	90(58.8)	34(72.3)	0.13
Ticagrelor	121(60.5)	33(50.8)	88(65.2)	0.11	87(56.9)	34(72.3)	0.08
Clopidogrel	3(1.5)	0(0.0)	3(2.2)	0.55	3(2.0)	0(0.0)	0.81

583 BMI, body mass index; CPR, cardiopulmonary resuscitation; DAPT, dual antiplatelet therapy;

584 IABP, intra-aortic balloon pump;

585

Table 2. Treatment characteristics and hospital course of patients who had a bleeding event and

587 those without bleeding events.

	Overall cohort	No bleeding (N=65)	Major bleeding (N=135)	P value	
	(N=200)	(11-03)	(N-135)		
Transfusions during	the hospitalizat	ion			
Red blood cells,	4.5(1.0,10.0)	1.0(0.0,2.0)	7.0(4.0,12.0)	<0.001	
units					
Platelets, units	1(0.0,4.0)	0.0(0.0,1.0)	2.0(0.0,5.0)	<0.001	
Fresh Frozen	1.0(0.0,3.0)	0.0(0.0,0.0)	1.0(0.0,3.0)	<0.001	
Plasma, units					
Hospital Course					
Renal Replacement	55(27.5)	14(21.5)	41(30.4)	0.25	
Therapy, N(%)					
Days on continuous	6.0(4.0,18.0)	3.5(3.0,4.0)	8.0(4.0,20.0)	0.20	
dialysis*(N=14)					
Thrombosis, N(%)	47(23.5)	11(16.9)	36(26.7)	0.16	
Extubation, N(%)	53(26.5)	13(20.0)	40(29.6)	0.20	
Days on	8.0(6.0,13.0)	6.0(5.0,8.0)	9.0(6.0,14.0)	0.05	
mechanical					
ventilation**					
(N=53),					
Days on VA	4.0(3.0,5.0)	3.0(2.0,4.0)	4.0(2.0,5.0)	0.05	
ECMO					
VA ECMO	95(47.5)	21(32.3)	65(48.1)	0.19	
decannulation,					
N(%)					
Length of hospital	8.0(2.0,20.5)	4.0(2.0,14.0)	10.0(3.0,22.0)	0.01	
stay, days					
Survival to hospital	64(32.0)	17(26.2)	47(34.8)	0.29	
discharge, N(%)					

*calculated for patients who survived to discontinuation of continuous dialysis

⁵⁸⁹ **Including patients who survived to liberation from mechanical ventilation

590 Table 3. Treatment characteristics and hospital course of patients who had a thrombotic event

591 including arterial thrombosis and VTE and those without thrombosis.

	No	Any	Р	No	Arterial	Р	No VTE	VTE	Р
	thrombosi	Thrombosi	value	arterial	thrombosis	valu	(N=178)	(N=22)	value
	s (N=153)	s (N=47)		thrombi	(N=31)	e			
				(N=169)					
Transfusions	during the ho	ospitalization							
Red blood	4(1,9)	7(2,12)	0.01	4.0(1.0,9.	7.0(2.0,12.	0.05	4.0(1.0,9.	7.0(2.8,12.0	0.07
cells, units				0)	0)		3))	
Platelets,	1.0(0.0,3.	2.0(0.0,5.0	0.005	1.0(0.0,3.	2.0(0.0,6.0	0.06	1.0(0.0,4.	2.0(1.0,5.5)	0.02
units	0))		0))		0)		
Fresh	1(0,2)	0(0,2)	0.50	0(0,2)	1(1.3)	0.39	1(0,2)	0(0,1)	0.09
frozen									

plasma, units									
Hospital cou	rse								
Renal Replaceme nt Therapy	37(24.2)	18(38.3)	0.09	40(23.7)	15(48.4)	0.00 9	49(27.5)	6(27.3)	1.00
Days on continuous dialysis* (N=14)	4.5(2.8,11 .3)	17.0(6.0,22 .0)	0.12	5.0(3.0,18 .0)	12.0(4.0,12 .0)	0.39	5(3,12)	22(4,)	0.18
Major bleeding event	99(64.7)	36(76.6)	0.18	111(65.7)	24(77.4)	0.28	118(66.3)	17(77.3)	0.42
Extubation, N(%)	37(24.2)	16(34.0)	0.25	48(28.4)	5(16.1)	0.23	39(21.9)	14(63.6)	<0.00 1
Days on mechanical ventilation* * (N=53), N(%)	7.0(5.5,11 .0)	11.5(6.5,18 .5)	0.07	7.5(6.0,13 .0)	13.0(8.0,17 .0)	0.17	7.0(6.0,11 .0)	11.5(7.5,15. 5)	0.09
VA ECMO decannulati on, N(%)	60(39.2)	26(55.3)	0.07	73(43.1)	13(41.9)	1.00	68(38.2)	18(81.8)	<0.00 1
Length of VA ECMO run days	3.5(2.4)	4.8(3.1)	0.008	3.6(2.5)	4.9(3.1)	0.04	3.7(2.6)	4.8(2.9)	0.12
Length of hospital stay, days	6(2,18)	15(5,29)	<0.00 1	8(2,21)	10(3,22)	0.37	6.0(2.0,17 .3)	28.0(15.0,3 7.8)	<0.00 1
Survival to hospital discharge, N(%)	46(30.1)	18(38.3)	0.38	58(34.3)	6(19.4)	0.15	49(27.5)	15(68.2)	<0.00 1

593

595 596

Figure 1. Hematologic markers on arrival to the intensive care unit stratified by patients with and without thrombosis and those with and without major bleeding.



598

599	Figure 2. Characteristics of major bleeding events. A. Sites of major bleeding. B. Percentage of
600	admitted patients who had a major bleeding event. C. Percentage of patients who had a major

601 bleeding event depending on admission fibrinogen level.



603 Figure 3. Characteristics of thrombotic events. A. Percentage of patients with different sites of

604 thrombosis with VTE(green) and arterial thrombosis (pink). B. Percentage of admitted patients

605 who present thrombosis per day of admission. * arterial thrombosis refers to aorta and/or SMA

606 thrombosis.

607



610

- Figure 4. Central figure. Rates of bleeding and thrombosis. Multivariable model of risks of
- 613 bleeding and thrombosis. * denotes statistical significance.
- 614

615



- 616 617
- 618
- -